Oppenheimer raised the firm’s price target on Regeneron to $1,125 from $1,050 and keeps an Outperform rating on the shares. The analyst cited a “plethora of stock drivers upcoming” for Regeneron, including what should be a strong launch of Eylea HD, sales of Libtayo now annualizing over $1B, and the expectation of two oncology assets (odronextamab and linvoseltamab) to be approved by the end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron’s treatment of Hemophilia B granted FDA orphan designation
- Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
- Regeneron to host conference call
- Regeneron price target raised by $27 at Morgan Stanley, here’s why
- Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year